Key Takeaways
- Revenue surges 21% YoY, export recovery sharp: Q4 revenue hit INR 843 crore as exports jumped to INR 88 crore from INR 38 crore a year ago, while Chinese destocking tapered and key molecule prices stabilized.
- Margins expand, with a clear FY26 step-up promised: EBITDA margin reached 16% this quarter, and management guides to 18–20% in FY26, driven by operating leverage, new products, and backward integration.
- The INR 1,000 crore FY26 target is backed by capacity and registrations: Capacity utilization in the technical segment is only ~62%, new US and EU product registrations are converting to orders, and Shalvis Specialities begins contributing next quarter.
- Working capital swelled on a deliberate inventory bet: Operating cash flow collapsed to INR 2 crore because the company is holding higher inventory to serve MNC customers who now give only 15–30 days’ notice, a structural shift that keeps working capital elevated near 220 days.
- What to watch next quarter: Whether the early monsoon actually pulls demand forward, the pace of debtor normalization after the March-April slippage, and the first revenue contribution from Shalvis Specialities.
Demand & Pricing Environment
- Chinese pressure easing: Aggressive destocking by Chinese manufacturers has tapered, reducing the oversupply that depressed prices last year. Prices for Captan, Prosulfocarb, and Folpet are now stable with no decline this quarter.
- Export demand recovering: Export turnover more than doubled YoY to INR 88 crore, and management sees the US tariff situation as a net positive for its positioning in American markets.
- Demand visibility is structurally shorter: MNC customers have shifted from giving 6–9 month order windows to just 15 days to 1 month, forcing the company to hold higher finished-goods inventory to avoid losing seasonal business.
- Weather-driven unpredictability: Demand is becoming harder to forecast because geographical and weather conditions are changing rapidly, shifting consumption between regions year to year. An early monsoon this year is expected to pull herbicide demand forward into the sowing season.
D. K. Jain: "Export side demand is also picking up madam now. There has been -- in the last years, the oversupply was there from Chinese manufacturer, but now slowly it is getting reduced and the demand is increasing. And with this American tariff situation, we are slightly positively poised for U.S. markets."
Revenue Growth Levers
- Capacity utilization has room to run: Technical segment utilization rose from ~41% to ~62% but still has significant headroom; formulations are already at 95%+, prompting expansion plans. Management states the existing asset base can support INR 1,100 crore of revenue if demand materializes.
- New product registrations converting to orders: Four EU/UK registrations (1 insecticide, 2 herbicides, 1 fungicide) and two US registrations were secured. Commercial supplies for one US product began this quarter, with the second expected to start within a month; European orders are in advanced discussion.
- Shalvis Specialities coming online: The new facility will start contributing from Q1 FY26, built in small blocks that add revenue step by step rather than in a single lump.
- Japanese collaboration scaling gradually: Commercial supplies to the Japanese partner grew from a small quantity last year to a bigger one this year, with discussions underway for additional molecules. Management does not currently envisage it reaching INR 100 crore but says it will exceed that with more products.
- Formulations running above 20% CAGR: Bulk formulation exports jumped from INR 10–12 crore to ~INR 50 crore, and the B2C domestic business is also growing; management expects 20% growth to be maintained this year.
Margins & Profitability
- Q4 margin expansion driven by stability and leverage: EBITDA margin reached 16% as raw material prices stabilized and higher volumes flowed through the fixed-cost base.
- FY26 margin bridge to 18–20%: The guided improvement rests on three legs: operating leverage from rising capacity utilization, introduction of new higher-margin products, and backward integration of select existing products.
- Long-term aspiration is a return to ~25%: Management believes it can recover peak margins over a few years through backward integration, operating optimization, and selecting products with inherently higher margins.
- Domestic and export margins are comparable: Prices differ by only ~0.5% between domestic and export markets; the only structural difference is duty on imported raw materials used for export production.
D. K. Jain: "Sir, we -- it will be our effort and continuous effort what we are making to increase the total overall market margin levels to the earlier one about 25%. And we feel that we should be able to do that in few years of time by backward integrating the products, by optimizing the operating conditions, then by selecting products with slightly higher margin levels."
Working Capital & Cash Flow
- Operating cash flow collapsed to INR 2 crore: The primary driver was a sharp increase in debtors, as some large buyers who were due to remit in March paid only in April. Domestic technical sales also carry longer credit periods than exports.
- Inventory is structurally higher, not a one-off: The shift by MNC customers to 15–30 day order windows means the company must hold finished goods ready to ship on short notice. Management has made a deliberate decision to carry this inventory rather than risk losing seasonal demand.
- Pretilachlor inventory is being worked down: Stock levels reduced this quarter and will see a significant further reduction by June.
- Normalized working capital pegged at ~220 days: Management expects this to come down by 10–15 days over coming quarters as the debtor position normalizes, but the inventory component is likely to stay elevated given the new customer behavior.
Strategic Initiatives & Competitive Position
- Backward integration as a moat: Management argues its backward integration initiative positions it competitively against global manufacturers, particularly Chinese players, across several key products.
- Antidumping filing in process: The company proactively filed for antidumping measures on Pretilachlor Technical; the Ministry of Commerce has recommended it, but the Ministry of Finance has not yet notified the duty. If imposed, volumes would be largely unchanged but prices and revenue would rise proportionately.
- CRDMO opportunity being explored: The company is actively collaborating with international firms to transition their research-stage products to commercial scale, with multiple global entities evaluating the initiative.
- Pretilachlor capacity expansion on track: 8,500 tons of capacity will be in place by August, targeting a domestic market of 10,000–12,000 tons that is currently largely import-dependent. Management expects 20% compounded growth from this product over the next 2–3 years.
- Global marketing venture still taking shape: The plan to source technical material from other manufacturers and sell formulations abroad is still in formation and will take time to materialize.
Anand Swarup Agarwal: "Our strategic initiative of backward integration positions us comparatively against global manufacturers, particularly those from China, in several key products."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | INR 1,000 crore | FY26 |
| EBITDA margin | 18% to 20% | FY26 |
| Revenue growth CAGR | 15% to 20% | Next 2–3 years |
| Capex outlay | INR 116 crore (IPL + Shalvis) | FY26 |
| Cumulative capex | Over INR 200 crore across existing facility and Shalvis | Over 2 years |
| Pretilachlor capacity | 8,500 tons installed | By August |
| Pretilachlor growth | 20% compounded | Next 2–3 years |
| Formulations growth | 20% maintained | FY26 |
| Key molecule demand growth (Captan, Prosulfocarb, Folpet) | 10% to 15% | FY26 |
| H1 revenue split | ~55% of full-year revenue | FY26 |
| Working capital days | Normalize to ~220 days, then reduce by 10–15 days | Coming quarters |
| Long-term EBITDA margin | Return to ~25% | "Few years" |
| Debt position | Remain debt-free, fund all expansion from internal accruals | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹211 cr, total revenue for the quarter |
| FY25 revenue | ₹844 cr, +21% YoY |
| EBITDA | ₹35 cr, +373% vs same quarter last year |
| EBITDA margin | 16%, margin expansion due to price stability and higher operating leverage |
| Net profit | ₹22 cr, PAT margin 10%, expanded by 950 bps YoY |
| FY25 net profit | ₹82 cr, +37% YoY, PAT margin 9.7% |
| FY26 revenue guidance | ₹1,000 cr, projected for next fiscal year |
| FY26 EBITDA margin guidance | 18% to 20%, improvement from current 16% |
| Revenue growth outlook | 15% to 20% CAGR in near next 2 to 3 years |
| Export revenue (Q4) | ₹88 cr, vs ₹38 cr in same period last year |
| FY25 export revenue | ₹315 cr, vs ₹269 cr in FY24 |
| FY25 domestic revenue | ₹513 cr, vs ₹410 cr in FY24 |
| Technical segment capacity utilization | ~62%, increased from ~41%, up approximately 50% |
| Formulation capacity utilization | upward of 95%, prompting plans for expansion |
| FY26 planned capex | ₹116 cr, for India Pesticides and Shalvis Specialities |
| Working capital days | ~250 days last quarter, normalized going forward ~220 days |
| Pretilachlor revenue | in excess of ₹100 cr this molecule, vs ₹70 cr last year |
| Pretilachlor capacity expansion value | more than ₹300 cr at 8,500 tons capacity |
| Bulk formulation exports | ~₹50 cr in FY25, up from ₹10-12 cr in FY24 |
| Formulations business growth | more than 20% compounded |
| Operating cash flow from operations (FY25) | ₹2 cr, reduced due to higher debtor days and inventory |
| Registrations received in FY25 | 4 technical, 19 formulations from CIB India; 4 in EU/UK, 2 in USA, 2 formulations in Australia |